HEMLIBRA

May 13, 2024

CAR-T therapy has been given the green light for treating blood cancers, but it hasn’t demonstrated sustained effectiveness against solid tumors thus far. The focus of ongoing CAR-T development leans heavily toward blood cancers rather than solid ones. On the other hand, bispecific antibodies have gained approval f...

Jul 14, 2023

Hemophilia A is a rare genetic bleeding disorder that primarily affects males. Hemophilia A is the most common type of hemophilia, accounting for approximately 80% of all cases. It is estimated to occur in about 1 in 5,000 to 10,000 male births. As per the Centers for Disease Control (CDC) (2020), the estimated pre...

Nov 07, 2022

Hemophilia A treatment scenario before the launch of HEMLIBRA Despite the ups and downs throughout history, the management of hemophilia A patients substantially improved over the past 40 years. The groundbreaking discovery of cryoprecipitate in 1964 marked the beginning of the modern progression of hemophilia t...